Carlsmed (CARL) Stock Price

Carlsmed Price

NYSE·CLOSED
17.42
​
Market closed

For Carlsmed, the net margin of -91.5% is up versus -137.2% a few years ago. The consensus 12-month price target for Carlsmed is 18.50 USD, about 6.2% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.

Carlsmed stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carlsmed business model & stock analysis

Carlsmed, Inc. generates revenue through its aprevo technology platform, which provides AI-based solutions for the surgical workflow. The platform includes pre-operative AI-enabled planning software that uses diagnostic imaging and algorithms to create personalized surgical plans and design aprevo interbody implants. Intra-operative advanced visualization tools support precision placement of these implants, while post-operative data collection offers insights to refine future planning. The company targets medical professionals and hospitals in the United States, focusing on lumbar interbody fusion procedures. Its products are sold under the aprevo brand, with the platform available in the U.S. market for surgical planning and implant design. Carlsmed's revenue streams come from the commercial sale of its aprevo technology platform, which integrates pre-operative planning, intra-operative visualization, and post-operative data analytics. The platform is specifically designed for lumbar interbody fusion procedures, addressing the needs of healthcare providers seeking to enhance surgical precision and outcomes. By leveraging AI-driven tools, Carlsmed enables personalized implant design and real-world data collection to improve surgical planning processes. The company's offerings are marketed to hospitals and surgeons in the U.S. healthcare sector, emphasizing the aprevo brand's role in digital surgical planning. The aprevo technology platform serves as Carlsmed's core product, offering a comprehensive solution for surgical workflows. Its pre-operative software utilizes standard-of-care imaging and AI algorithms to develop patient-specific plans and implant designs. Intra-operative tools provide advanced visualization for precise implant placement, while post-operative data collection informs continuous improvement of the planning process. The platform is indicated for use in lumbar interbody fusion procedures and is commercially available in the United States, targeting healthcare institutions that prioritize AI-enhanced surgical planning and outcomes.

Frequently asked questions about Carlsmed

Analysts currently set an average price target of 18.50 USD for the Carlsmed stock (median: 18.50 USD), implying +6.2 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the Carlsmed stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Carlsmed to generate revenue of 79.25 M USD and earnings per share of -1.53 USD.

Converted at the current exchange rate, the Carlsmed share trades at 15.87 EUR (17.42 USD).

The expected revenue of Carlsmed is 79.25 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Carlsmed is -40.47 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Carlsmed is currently -11.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Carlsmed stock.

The price-to-sales ratio (P/S) of Carlsmed is currently 5.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Carlsmed stock.

The Eulerpool Quality Score for Carlsmed is 2/10.

The ISIN of Carlsmed is US14280C1053. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Carlsmed is CARL. The ticker symbol is used to trade Carlsmed shares on the stock exchange.

Fair ValueTerminal
16.72 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
427,795.28 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website carlsmed.com
Currency
USD
Initial public offering
Jul 23, 2025
ISIN
US14280C1053
Cusip
14280C105
Market capitalization
463.20 M USDSmall Cap
52-Week Range
PEG
0.49
P/E ratio
P/Ee 2025
-7.77
P/Ee 2026
-11.41
P/Ee 2027
-11.28
P/Ee 2028
-16.12
P/Ee 2029
-22.27
P/S
P/Se
9.23
EV/EBIT
—
P/B Ratio
18.10
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-121.19 %
Last updated Nov 22, 2026, 3:42 AM

Carlsmed Peer Group

All fundamentals and in-depth analysis of Carlsmed

Our stock analysis for Carlsmed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Carlsmed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.